Eric Kauderer-Abrams, head of biology at Anthropic, shares insights into the company's innovative use of AI for life sciences. He highlights the unique approach Anthropic takes with its language models and explains why scientists can have confidence in these large language models (LLMs) for advancing research and discovery in life sciences.
A crucial insight from the past five years is the urgent need for public health to improve its approach to managing uncertainty.
Trust in public health institutions has been waning over the years. Popular YouTuber Doctor Mike proposes new strategies to enhance social media engagement and restore public confidence in healthcare.
The American Medical Association (AMA) has unveiled a new Center for Digital Health and AI. AMA CEO John Whyte provides insights into the center's mission and goals in a recently published Q&A.
Recent announcements from AI startups Abridge and OpenEvidence at HLTH reveal that these companies, previously distinct in their approaches, are now directly competing to attract physician users.
Recent data presented at ESMO 2025 strengthens the evidence that novel blood tests can assist doctors in determining which cancer patients require additional therapy and which patients may avoid further treatment.
Two prominent institutions have joined forces to develop a new publication aimed at serving as an alternative to the CDC's renowned Morbidity and Mortality Weekly Report (MMWR). This collaboration seeks to provide fresh perspectives and enhance public health reporting.
Promising developments in breast cancer treatment have emerged as AstraZeneca and Gilead report positive results from their recent trials. These findings bring hope for new therapies targeting aggressive forms of the disease, potentially improving outcomes for patients.
At a significant oncology conference, Merck presented groundbreaking data on cancer drugs that could play a crucial role in shaping the company's future success.
Amgen is actively filling in the gaps and addressing ongoing questions related to its gastric cancer drug, aiming to clarify the drug's potential and development progress.